Patent ductus arteriosus: how important to which babies?

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Clinical Trials

Background:

• Patent ductus arteriosus (PDA) is common in preterm infants.
• PDA can lead to significant complications.
• Interventions aim to close PDA and prevent adverse outcomes.

Purpose of the Study:

• To review randomized controlled trials (RCTs) comparing surgical closure versus indomethacin for PDA in preterm infants.
• To assess the impact of these interventions on mortality, chronic lung disease, and other morbidities.

Main Methods:

• Systematic review and overview of 21 RCTs.
• Included trials with surgical closure or indomethacin therapy for PDA.
• All trials had backup treatment protocols for persistent PDA.

Main Results:

• No significant overall effect on mortality or chronic lung disease was found.
• A trend towards reduced chronic lung disease was observed in trials treating PDA at a presymptomatic stage.
• Early indomethacin treatment was associated with a reduced incidence of periventricular hemorrhage.
• PDA size at 3 days correlated with infant condition, not gestational age or birth weight.
• Infants with moderate-to-large PDA had lower blood pressure from 12 hours onward.

Conclusions:

• Current evidence does not support a significant benefit of surgical closure or indomethacin for PDA on mortality or chronic lung disease in preterm infants.
• Early indomethacin may offer a neuroprotective benefit by reducing periventricular hemorrhage.
• PDA size and hemodynamic significance are related to infant illness severity and impact blood pressure.
• Further research may be needed to identify optimal timing and patient selection for PDA interventions.